Recently, ORIENT-31, a prospective, double-blind, and multicenter phase 3 trial, revealed that combined anti-PD-1 antibody and anti-VEGF antibody treatments with chemotherapy significantly prolonged PFS compared with chemotherapy alone in patients with EGFR-mutant nonsquamous NSCLC who had disease progression after EGFR-TKI therapy [18]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.